Merck + Co., Inc.

Rutgers, the State University of New Jersey

Merck Sharp + Dohme Corp.

University of Medicine and Dentistry of New Jersey

Jennifer Nielsen Kahn

Rosemarie Kelly

Cameron M Douglas

David S Perlin

Steven Park

Stephen A Parent

Janet C Onishi

Louis Kaplan

Kevin M Byrne

Nancy R Morin

Mohammed El-Sherbeini

Gary L Chrebet

Joseph A Clemas

Elizabeth A Register

Forrest Foor

Gan-Ju Maria Shei

Stephen Authur Parent

Richard J Monaghan

Naasa M Ramadan

Jean A Marrinan

Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.

Assays for resistance to echinocandin-class drugs

DNA encoding 1,3 beta-D glucan synthase subunits

Disclosed are new Aspergillus niger mutants which can be used for identifying active FK-506/ rapamycin type, or cyclosporin A type inununosuppressants in a broth, natural product extract, or composition exhibiting inununosuppressant activity. Specifically disclosed are the new mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A.

Aspergillus niger mutants

Growing community of inventors

East Brunswick, NJ, United States of America

Jennifer Nielsen Kahn